The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize a diversified mix of ETFs and individual stocks across sectors, balancing dividend income, growth, and capital appreciation while mitigating downside risk. Key metrics include a 3.75% weighted average dividend yield, low payout ratios, and low beta factors, supporting long-term portfolio resilience.

seekingalpha.com - 2026-07-13 13:45:49

Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growth innovative assets.

fool.com - 2026-07-09 12:12:04

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

fool.com - 2026-07-09 08:15:04

Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.

marketbeat.com - 2026-07-08 12:36:02

Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avidity's del-brax and Ionis's pelacarsen, both late-stage assets, offer multibillion-dollar peak sales potential with pivotal data expected in the second half of the year.

seekingalpha.com - 2026-07-07 08:40:52

NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.

zacks.com - 2026-07-06 15:41:05

The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.

wsj.com - 2026-07-06 01:52:00

Swiss drugmaker Novartis said on Monday it had ​agreed to pay up to $1.5 ‌billion for U.K.-based biotechnology firm Myricx Bio in a deal expected ​to close in the second ​half of 2026.

reuters.com - 2026-07-06 01:26:17

Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.

zacks.com - 2026-07-02 15:16:14

The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story:

marketbeat.com - 2026-07-01 11:05:28

Novartis (NVS) is sitting at the center of a fast-growing oncology market as radioligand therapy gains momentum in cancer treatment. The therapy uses targeted r

gurufocus.com - 2026-06-25 08:34:00

Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth ​up to about $1.9 billion, aiming to develop therapies ‌for historically hard-to-drug cancer targets.

reuters.com - 2026-06-24 08:15:00

BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop and commercialize small molecule therapies against promising but historically undruggable oncology targets. The agreement underscores the productivity and breadth of Antares' discovery capabilities, which have repeatedly delivered development candi.

businesswire.com - 2026-06-24 07:00:00

The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.

zacks.com - 2026-06-23 17:21:05

Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.

zacks.com - 2026-06-15 11:30:30

The Schwab Fundamental International Equity ETF (NYSEARCA:FNDF) pays semi-annual distributions sourced from a basket of developed-market dividend payers outside the United States, and at roughly $54 a share the fund has quietly become a core income holding for investors who want global diversification without chasing yield.

247wallst.com - 2026-06-13 10:00:14

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido®  (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial7. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines7. “Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité–Universitätsmedizin Berlin, Germany. “The RemIND results across the three most common CIndU subtypes highlight the potential of Rhapsido as an important new treatment option for patients with significant unmet need.” The three most prevalent CIndU subtypes are symptomatic dermographism (SD), cold urticaria, and cholinergic urticaria, with SD being the most common8. Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Rhapsido for the treatment of SD subtype and will continue additional filings to health authorities globally throughout 2026. Rhapsido is approved for use in the U.S., European Union, China and several other countries for the treatment of chronic spontaneous urticaria (CSU), in adult patients with inadequate response to H1-antihistamines. “Rhapsido significantly improves symptom control for patients living with the three most common subtypes of chronic inducible urticaria, and it has the potential to become the first approved targeted therapy. This is a major step forward for CIndU patients who have limited options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “The CIndU data presented today are consistent with Rhapsido's proven efficacy and favorable safety profile in chronic spontaneous urticaria and demonstrate Novartis' commitment to developing truly meaningful innovation for patients with complex immune-mediated diseases.” Primary endpoint results at Week 12 in the RemIND trial1

globenewswire.com - 2026-06-12 05:36:00

Novartis said on Thursday an experimental drug, which it acquired ​as part of its $12 billion takeover of ‌Avidity, showed promise in an early-to-mid-stage study in patients with a type ​of genetic muscle disorder characterized ​by slowly progressive muscle weakness.

reuters.com - 2026-06-11 17:41:12

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.

zacks.com - 2026-06-11 14:26:18

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

zacks.com - 2026-06-11 14:26:14

Novartis AG (NYSE:NVS) said Thursday that the biomarker cohort of its Phase 1/2 FORTITUDE study evaluating investigational therapy del-brax met both its primary and key secondary endpoints in patients with facioscapulohumeral muscular dystrophy (FSHD), a rare neuromuscular disease.

benzinga.com - 2026-06-11 09:14:12

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

etftrends.com - 2026-06-11 07:14:42

Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax indicates potential to become the first disease-modifying treatment for FSHD, a progressive and irreversible neuromuscular disease affecting approximately 45-87k people in the US and EU Novartis plans to engage global regulatory authorities on Phase I/II data; Phase III study currently enrolling Basel, June 11, 2026 – Novartis announced today that the biomarker cohort of the FORTITUDE Phase I/II study of del-brax met its primary and key secondary endpoints, with reductions in KHDC1L (cDUX) and creatine kinase biomarker levels indicating both strong target engagement and reduction in muscle damage in patients with facioscapulohumeral muscular dystrophy (FSHD).

globenewswire.com - 2026-06-11 01:00:00

BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company pioneering proximity-induced therapeutic modalities, today announced a multi-year collaboration with Novartis to discover and design molecular glue drugs for challenging therapeutic targets across multiple disease areas. The collaboration expands the existing relationship between the companies and reflects a shared commitment to unlock the full value of induced proximity approac.

businesswire.com - 2026-06-10 07:00:00

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU). “The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.” Abstracts accepted by EAACI include:

globenewswire.com - 2026-06-08 03:00:00

Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.

zacks.com - 2026-06-05 13:05:19

Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia® (atrasentan) versus placebo in adults with IgA nephropathy (IgAN)1 ,2. Results were published in The Lancet and presented at the European Renal Association (ERA) Congress. Estimated glomerular filtration rate (eGFR) change from baseline favored Vanrafia, alongside sustained reductions of protein in the urine through end of treatment. Benefits were consistent across different measures of kidney function and in patients additionally receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors1,2. “These results provide robust evidence of clinically meaningful slowing of kidney function decline over more than two years of treatment, reinforcing findings from the earlier analysis of proteinuria reduction,” said Richard Lafayette, MD, FACP, Professor of Medicine, Nephrology, Director of the Glomerular Disease Center at Stanford University Medical Center, and ALIGN Study Investigator and Steering Committee Member. “They highlight the role of a highly selective endothelin A receptor antagonist as part of an evolving treatment approach for IgAN.”

globenewswire.com - 2026-06-04 06:15:00

Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustained remission rates vs placebo and significant steroid sparing8. Published in the New England Journal of Medicine and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress, Phase III REPLENISH data showed that the effect of Cosentyx treatment was sustained through week 52 in this investigational use8.

globenewswire.com - 2026-06-03 11:30:00

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

fool.com - 2026-06-02 17:12:15

Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London, advancing scientific insight into high-burden autoimmune diseases.

globenewswire.com - 2026-06-01 01:15:00

Novartis said on Sunday that early data from ‌its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.

reuters.com - 2026-05-31 07:16:57

Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC; androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) compared to SoC alone in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). These PSMAddition data were presented as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

globenewswire.com - 2026-05-31 01:15:00

Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year's European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce our ambition to advance scientific understanding across progressive immune-mediated kidney diseases and support the evolution of kidney care.

globenewswire.com - 2026-05-26 01:15:00

Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress.

globenewswire.com - 2026-05-21 01:15:00

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

fool.com - 2026-05-18 21:00:00

Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.

zacks.com - 2026-05-18 13:01:22

Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.

globenewswire.com - 2026-05-17 15:30:00

On Tuesday, Isomorphic Labs, the Alphabet-founded firm that uses AI to accelerate drug development, said that it had raised $2.1 billion from investors led by Thrive Capital. That's a boatload of cash for a drug developer, and represents the second largest ever fundraise for a biotech company behind only Altos Labs, according to trade publication Endpoints News.

forbes.com - 2026-05-13 18:15:17

Investors need to pay close attention to NVS stock based on the movements in the options market lately.

zacks.com - 2026-05-13 10:05:32

Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research. The start of construction on the company's first Texas‑based manufacturing facility brings US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide. “Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Vas Narasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.” This expansion reinforces Novartis' leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the site is expected to become operational in 2028 and create new US-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities.  US Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the US Ralf Heckner, Texas State Senator Brent Hagenbuch, Texas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth joined Novartis leadership, employees, and community partners to celebrate the start of construction.  “I'm pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” said Texas State Senator Brent Hagenbuch. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.” The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest US RLT manufacturing network and further builds on the company's longstanding track record of enabling >99% of doses to be administered on the planned day of treatment. Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centers critical to delivering treatment as planned. In April 2025, Novartis committed $23 billion over five years to grow its US research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction – part of the company's broader effort to manufacture all key medicines for US patients in the US, supporting supply resilience and dependable delivery of medicines. The Denton groundbreaking builds on rapid progress across Novartis' US investment plan.

globenewswire.com - 2026-05-07 09:00:00

Swiss drugmaker Novartis ​said on Tuesday ‌that it is set ​to ​cut around 220 jobs ⁠in ​Germany as part ​of the planned closure of ​a production ​site by the ‌end ⁠of 2028.

reuters.com - 2026-05-05 08:16:58

On April 30, 2026, Novartis AG (NVS) shares rose 3.4% today, bringing the current price to $147.85. This price is within a 52-week range of $104.93 to $170.46,

gurufocus.com - 2026-04-30 17:06:00

Concurrent Investment Advisors LLC raised its holdings in shares of Novartis AG (NYSE: NVS) by 36.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,815 shares of the company's stock after buying an additional 3,967 shares during the quarter.

defenseworld.net - 2026-04-29 14:10:57

Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giants have recently said that Europe risks losing out on new medicines as drug prices in the U.S. market are tied to lower prices elsewhere under Trump's MFN policy.

cnbc.com - 2026-04-29 05:32:51

Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year guidance was reaffirmed. Entresto U.S. sales eroded faster than I expected, but easier Y/Y comps and robust pipeline support a return to growth. NVS's key products Kisqali, Kesimpta, Leqvio, and Pluvicto continue to outperform, and Rhapsido is off to a strong start in the CSU market with additional clinical trial readouts on the way.

seekingalpha.com - 2026-04-28 15:18:18

Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.

youtube.com - 2026-04-28 13:04:31

NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and pipeline advances.

zacks.com - 2026-04-28 12:16:08

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-04-28 10:31:05

Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugmaker declined about 3% in premarket trading on Tuesday following the earnings release.

invezz.com - 2026-04-28 04:58:46

Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.

youtube.com - 2026-04-28 03:54:24